Zacks.com on MSN20h
Syros Stock Plunges as Lead Cancer Study Fails to Meet Primary GoalShares of Syros Pharmaceuticals SYRS plunged 86.9% on Wednesday after a late-stage study of its only pipeline candidate, ...
Syros Pharmaceuticals' Phase 3 trial of tamibarotene in higher-risk myelodysplastic syndrome did not meet primary endpoints, ...
Syros Pharmaceuticals’ stock has declined sharply for the second time in the past three months as a Phase III trial with ...
Syros Pharmaceuticals’ blood cancer prospect tamibarotene has failed another study, triggering a default on a loan and ...
With the Phase III failure, Syros will discontinue the study of tamibarotene for myelodysplastic syndrome and will default on ...
Shares of Syros Pharmaceuticals collapsed in premarket trading Wednesday after the biopharmaceutical company's lead asset, tamibarotene, failed in a late-stage study in a rare blood cancer.
Syros Pharmaceuticals (SYRS – Research Report) received a Hold rating and price target from TD Cowen analyst Phil Nadeau yesterday. The company’s shares closed yesterday at $2.73. Nadeau covers ...
The SELECT-MDS-1 trial showed no significant complete response rate improvement with tamibarotene plus azacitidine for ...
Syros Pharmaceuticals Inc.’s phase III failure with oral retinoic acid receptor alpha agonist tamibarotene in myelodysplastic syndrome (MDS) meant not only severe stock damage but also defaulting ...
1d
Philadelphia, Pennsylvania-- (Newsfile Corp. - November 13, 2024) - Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of Syros Pharmaceuticals, Inc. ("Syros" or ...
Syros Pharmaceuticals announced that its phase 3 trial of tamibarotene in combination with azacitidine did not meet the primary endpoint for the treatment of myelodysplastic syndrome.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback